Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aphria Inc. stock logo
APHA
Aphria
$15.38
$15.48
$2.78
$32.29
$4.87B2.6721.83 million shsN/A
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
C$0.00
C$11.77
C$26.00
C$2.15BN/A229,895 shs4.61 million shs
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$26.28
$24.33M0.4124,502 shs237,144 shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$84.52
+0.2%
$83.60
$62.35
$90.04
$4.18B0.44297,189 shs38,352 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aphria Inc. stock logo
APHA
Aphria
0.00%0.00%0.00%0.00%0.00%
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%0.00%+10.14%-34.02%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
-1.71%-0.22%+4.12%+0.67%+33.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
1.6275 of 5 stars
3.00.00.04.20.00.80.0
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
4.119 of 5 stars
2.32.01.73.53.12.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aphria Inc. stock logo
APHA
Aphria
0.00
N/AN/AN/A
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
0.00
N/AN/AN/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
2.00
Hold$36.00∞ Upside
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.50
Moderate Buy$93.3310.43% Upside

Current Analyst Ratings Breakdown

Latest CARA, APHA, PBH, and AUP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
3/21/2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$96.00 ➝ $97.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aphria Inc. stock logo
APHA
Aphria
$405.96M12.00$0.09 per share166.43$4.80 per share3.20
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
C$57.59M0.00N/A6.75C$2.59 per share0.00
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.14B3.67$4.96 per share17.03$36.10 per share2.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aphria Inc. stock logo
APHA
Aphria
-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/A
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A-C$1.48N/AN/AN/AN/AN/AN/AN/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$209.34M$4.2919.7917.762.6919.13%12.36%6.39%8/14/2025 (Estimated)

Latest CARA, APHA, PBH, and AUP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q4 2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.30$1.32+$0.02$1.00$289.36 million$296.52 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.902.25%N/A44.29%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aphria Inc. stock logo
APHA
Aphria
0.25
2.36
1.17
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
2.69
11.93
11.02
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.56
3.68
2.20

Institutional Ownership

CompanyInstitutional Ownership
Aphria Inc. stock logo
APHA
Aphria
10.30%
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
99.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aphria Inc. stock logo
APHA
Aphria
1,200316.80 millionN/AOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
300128.40 millionN/ANot Optionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
54049.42 million48.75 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aphria stock logo

Aphria NASDAQ:APHA

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals TSE:AUP

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Prestige Consumer Healthcare stock logo

Prestige Consumer Healthcare NYSE:PBH

$84.32 -0.03 (-0.04%)
As of 11:34 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.